An interventional study of Goal-directed care bundle for neuroprotection and Usual Care in Cardiac Arrest and Post-cardiac Arrest Care, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.
Among the 37 studies in Heart Arrest with a site in China, this one is one of 6 that started in 2025, is one of 5 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 32nd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:
Central China Fuwai Hospital of Zhengzhou University · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–75
Tang Ziren · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18+
Renrong Gong · Sites in China
Ages 14–90 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,008 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 299 across the 9 interventional studies, 300 across the 28 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 177 studies on the registry; 80 are open to participants now.
Xiangya Hospital of Central South University has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Arrest with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07113769Central China Fuwai Hospital of Zhengzhou UniversityPlasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation | 2026-12-30 |
| NCT06353334Tang ZirenButylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) | 2026-12-31 |
| NCT06974682Capital Medical UniversityEffect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest | 2027-06-01 |
| NCT06992843Xiangya Hospital of Central South UniversityNeuroprotection Bundles For Comatose Survivors Following Cardiac Arrest | 2027-08 |
| NCT06241261The University of Hong KongArresting Early Childhood Caries With a Silver Diamine Fluoride Gel | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Heart Arrest with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators designed LAPTOPS to determine the effectiveness of a goal-directed neuroprotection bundles of active management including body temperature,PaCO2,PaO2,position,Blood glucose ,blood sodium,Blood pressure and Lactate vs. usual care in adult post-cardiac arrest care.
LAPTOPS is a large-scale pragmatic clinical trial to provide reliable evidence over the effectiveness of a widely applicable goal-directed care bundle in acute phase of adult post-cardiac arrest care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Management policy to receive a goal-directed care bundle that involves the rapid correction (\<24 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 72h or hospital discharge (or death, if sooner)
Other: Goal-directed care bundle for neuroprotection
Patients receive the usual management based on local guidelines and hospital's individual policy.
Other: Usual Care
Reducing lactate (Lac) to \<2 mmol/L within 24 hours.Maintaining systolic arterial pressure at 120-140 mmHg. Elevating the head-of-bed to 30 degrees. Maintaining body temperature ≤37.7°C. Maintaining PaO₂ at 70-100 mmHg. Maintaining PaCO₂ at 35-45 mmHg. Maintaining blood glucose at 7.8-10.0 mmol/L. Maintaining serum sodium level at 140-150 mmol/L. If any management parameter falls outside the target range, immediate correction is required within 24 hours of enrollment and must be sustained for 72 hours. Given the dynamic nature of some targets (e.g., mean arterial pressure, body temperature), a degree of flexibility is permitted in achieving these goals. Patients are considered to have successfully implemented the neuroprotection bundle if the achievement rate of individual targets is ≥80% and all targets are met. The medications(antipyretics, vasopressor agents) is acceptable to achieve these targets.
Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
Favorable neurological prognosis
Assessed using the CPC score, with a score of 1-2 being a favorable outcome.
Time frame: 90 days post cardiac arrest
GCS score
GCS score
Time frame: 7 days post cardiac arrest
CPC score
CPC score
Time frame: 1 day (discharge date)
GCS score
GCS score
Time frame: 1 day (discharge date)
Time to death
Number of days alive within 180 days from ROSC.
Time frame: 180 days
the length of ICU stay
the length of ICU stay
Time frame: The total length of IC-stay will be determined from the date of ICU admission until the patient is discharged from the Intensive Care Unit or the date of death from any cause, assessed up to 1 year after the first day of admission.
the length of hospital stay
the length of hospital stay
Time frame: The total length of hospital-stay will be determined from the date of ICU admission until the patient is discharged from the hospital or the date of death from any cause assessed up to 1 year after the first day of admission.
the length of mechanical ventilation
the length of mechanical ventilation
Time frame: Total ventilation time during ICU stay will be determined when the patient is discharged from the ICU or when the patient past away from any cause, assessed up to 1 year after the first day of admission.
the incidence of adverse event
The incidence of adverse effects during ICU treatment
Time frame: From the date of ICU admission until the patient is discharged from the Intensive Care Unit or the date of death from any cause, assessed up to 1 year after the first day of admission.
in-hospital mortality
in-hospital mortality
Time frame: The total length of hospital-stay will be determined from the date of ICU admission until the patient is discharged from the hospital or the date of death from any cause assessed up to 1 year after the first day of admission.
28-day mortality
28-day mortality
Time frame: 28 days post cardiac arrest
Quality of life assessment
Health-related Quality of Life - EQ-5D (Index value)
Time frame: 90 days post cardiac arrest
bundle compliance rate
referring to the proportion of patients whose management parameters are within the target ranges.
Time frame: 72 hours
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.
Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 22 months is below that.
Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiangya Hospital of Central South University →